The clinical and immunologic effects of a biosynthetic human leukocyte interferon, recombinant leukocyte A interferon (IFL-rA), are reported in eight patients with advanced cancer. Single escalating doses from 3×106 units to 198×106 units were given by intramuscular injection in a phase 1 study. Major toxic effects included pyrexia, fatigue, myalgia, and headache. Data on the effects of IFL-rA on lymphocyte subpopulations and peripheral blood mononuclear-cell surface β2-microglobulin are presented. Four of eight patients had objective tumor regression, indicating that further investigation of this biologically active material is warranted.
Horning SJ, Levine JF, Miller RA, Rosenberg SA, Merigan TC. Clinical and Immunologic Effects of Recombinant Leukocyte A Interferon in Eight Patients With Advanced Cancer. JAMA. 1982;247(12):1718-1722. doi:10.1001/jama.1982.03320370032025